Abstract
BTK Leu528Trp - a Potential Secondary Resistance Mechanism Specific for Patients with Chronic Lymphocytic Leukemia Treated with the Next Generation BTK Inhibitor Zanubrutinib
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have